Searchable abstracts of presentations at key conferences in endocrinology

ea0022p640 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a Phase II extension study

Boscaro Marco , Zhang Yilong , Sen Kapildeb , Maldonado Mario , Schoenherr Ulrike , Findling James

Introduction: Pasireotide reduced UFC levels in 22 of 29 patients with Cushing’s disease after 15 days’ treatment (Boscaro et al. JCEM 2009). Of these 22 patients, 5 achieved normalized UFC (UFC-responders) and 17 had reduced but not normalized UFC (UFC-reducers). Results of an extension phase to this study are presented.Methods: Patients with de novo or persistent/recurrent Cushing’s disease received pasireotide 600 μg ...